Oncomine cfNA Assays

Oncomine cfNA Assays are targeted next-generation sequencing (NGS) research panels designed to sensitively detect genomic alterations in cell-free nucleic acids (cfNA), including cfDNA and cfRNA, from liquid biopsy samples (i.e, blood, bile, cerebrospinal fluid, and urine). The assays provide multi-biomarker insights including single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and fusions when tissue samples are not available, or as a complement to tissue testing to better understand tumor heterogeneity.

Oncomine cfNA Assays are highly sensitive, achieving a limit of detection (LOD) down to 0.1% frequency (with a sensitivity of >90% and specificity of >98%), or 1 mutant copy in a background of 1,000 wild-type (WT) copies. To achieve a 0.1% LOD, 20 ng of input cfDNA is recommended. Lower amounts of cfDNA can be used, but the limit of detection may be higher depending on the input amount.  

Oncomine cfNA Assays are used to detect mutations present in cfNA from plasma isolated from blood. cfNA is of interest because it harbors the same genomic alterations present in the tumor, such as SNVs, indels, CNVs, and fusions.  In addition, the liquid biopsy assays can be used repeatedly to assess for changes as the tumor evolves over time. While Oncomine cfNA Assays are generally used to evaluate blood samples, researchers may also choose to evaluate other sample types such as bile, cerebrospinal fluid, or urine. 

Oncomine cfNA Assays are designed for use with the Ion Torrent NGS platforms including the Genexus System and GeneStudio S5 Systems. The Genexus System is a fast, easy, automated two-instrument NGS platform to bring the power of rapid NGS to your lab without the need for specialized sequencing or bioinformatics expertise. The GeneStudio S5 System is a scalable, flexible, and high-throughput NGS platform for a broad range of applications to achieve insights fast and efficiently.